The facility is expected to be operational in a few months post qualification and will house over 250 scientists
Biocon said its subsidiary has acquired a Chennai-based biological research facility from Pfizer Healthcare for an undisclosed amount. Biocon Biologics has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai, Biocon said in a statement.
“The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide,” Christiane Hamacher, CEO, Biocon Biologics said. This investment will allow the company to fast-forward development of its biosimilars from lab to pilot scale, he added.
The facility will house an early stage research and innovation centre, including a pilot scale R&D unit equipped with cell line development, drug product formulation laboratories and analytical R&D laboratories. The facility is expected to be operational in a few months post qualification and will house over 250 scientists. This acquisition provides Biocon Biologics a significant time advantage in comparison to setting up a greenfield R&D project and will accelerate the global development of its biosimilars portfolio, the company said. At present, the company has an R&D centre at Bengaluru. Biocon Biologics has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own